Depressive Symptoms in Schizophrenia Spectrum Disorders

Depressive symptoms are a frequent and disabling component of schizophrenia spectrum disorders (SSD), affecting a substantial proportion of patients across all stages of illness. These symptoms encompass persistent low mood, anhedonia, sleep disturbance and suicidal ideation, and may occur alongside positive symptoms such as hallucinations and delusions or emerge as secondary features related to medication effects or psychosocial stress. Their presence is strongly associated with poorer functional recovery, reduced quality of life and elevated suicide risk, yet they are often under-recognised in clinical practice. The symptom overlap between primary negative features of schizophrenia and co-morbid depression poses diagnostic challenges that necessitate specialised assessment tools. Neurobiological research has identified convergent alterations in frontal and subcortical circuits, with disruptions in white-matter integrity and functional connectivity mirroring patterns observed in major depressive disorder. Cognitive and clinical factors, including the duration of untreated psychosis and the severity of disorganised thought, further influence the onset and trajectory of depressive symptoms. Integrated management approaches that combine carefully selected pharmacological regimens, psychotherapeutic techniques and systematic screening are emerging as essential strategies to mitigate the global burden of depression in SSD and to improve long-term outcomes.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Depressive Symptoms in Schizophrenia Spectrum Disorders publication trend

The graph below shows the total number of articles in depressive symptoms in schizophrenia spectrum disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Schizophrenia Spectrum Disorders (SSD): A group of psychotic conditions characterised by hallucinations, delusions, disorganised thinking and reduced emotional expression.

Depressive Symptoms: Affective features including persistent low mood, loss of interest or pleasure, changes in appetite or sleep, and suicidal thoughts.

Positive and Negative Syndrome Scale (PANSS): A clinician-rated instrument measuring positive, negative and general psychopathology symptoms in schizophrenia.

Calgary Depression Scale for Schizophrenia (CDSS): A specialised scale designed to distinguish depressive symptoms from negative and extrapyramidal phenomena in schizophrenia.

T1-weighted Imaging: A structural MRI sequence used to assess grey-matter morphology by producing high-contrast anatomical images.

Functional MRI (fMRI): A neuroimaging technique that detects brain activity by measuring changes in blood oxygenation related to neural function.

Duration of Untreated Psychosis (DUP): The period between the onset of psychotic symptoms and the initiation of adequate treatment, associated with long-term outcome.

References

1. Effects of low-dose combined olanzapine and sertraline on negative and depressive symptoms in treatment-resistant outpatients with acute exacerbated schizophrenia. Frontiers in Pharmacology (2023).
2. A systematic review of structural and functional magnetic resonance imaging studies on the neurobiology of depressive symptoms in schizophrenia spectrum disorders. Schizophrenia (2024).
3. Untangling Depression in Schizophrenia: The Role of Disorganized and Obsessive-Compulsive Symptoms and the Duration of Untreated Psychosis. Biomedicines (2024).
4. Validation and optimal cut-off score of the World Health Organization Well-being Index (WHO-5) as a screening tool for depression among patients with schizophrenia. BMC Psychiatry (2024).